Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
New England Cord Blood Bank (NECBB) is a specialized healthcare company focused on the processing and cryopreservation of umbilical cord blood and cord tissue stem cells. Established in 1997 and based in Marlborough, Massachusetts, the company provides families with long-term storage solutions for newborn stem cells, which can be used in the treatment of over 80 diseases, including various cancers and blood disorders. NECBB operates an advanced, AABB-accredited and FDA-registered laboratory facility to ensure the highest quality standards for cellular processing. In June 2021, the company was acquired by Cryo-Cell International, a leader in the stem cell bank industry, enhancing its operational capabilities and market reach. Beyond cord blood, the company has historically offered related services such as dental pulp stem cell storage through its affiliated laboratories.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on New England Cord Blood Bank.